Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 10/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557323 | 0.94 | CCR3 (0.60) | CCR3MEN1POLBKMT2AHTR2A | |
| SCHEMBL3557299 | 0.88 | CCR3 (0.67) | CCR3MEN1POLBKMT2AHTR2A | |
| SCHEMBL3566218 | 0.87 | CCR3 (0.58) | CCR3MEN1POLBKMT2AHTR2A | |
| SCHEMBL27641304 | 0.81 | CCR3 (0.61) | CCR3MEN1KMT2AHTR2A | |
| SCHEMBL3557972 | 0.81 | CCR3 (0.65) | CCR3MEN1POLBKMT2AHTR2A | |
| SCHEMBL5541398 | 0.81 | UTS2R (0.70) | MEN1POLBKMT2AHTR2ASLC6A2 | |
| SCHEMBL3563441 | 0.81 | RAB9A (0.42) | CCR3MEN1POLBKMT2A | |
| SCHEMBL3556275 | 0.80 | MAPK1 (0.47) | MEN1POLBKMT2APRMT6CARM1 | |
| SCHEMBL6197244 | 0.80 | CCR3 (0.56) | CCR3MEN1POLBKMT2AHTR2A | |
| SCHEMBL4861307 | 0.80 | CCR3 (0.62) | CCR3MEN1POLBKMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | claimed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | claimed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| CN-1856305-B | Pyridine derivatives as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD | 2010-04-28 | — | — | CN | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1856305-A | Pyridine derivatives and their use as urotensin II antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | CCR3 2602/4885MEN1 1845/4885POLB 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.